OKI granules
Manufacturer: Dompé Farmaceutici S.p.A.
Active ingredient: ketoprofen
Dosage form: granules for the preparation of oral solution
There are contraindications. Read the drug label and check with your physician before use.
One of the representatives of propionic acid derivatives with a strong analgesic and balanced anti-inflammatory action is ketoprofen lysine salt. The drug stabilizes lysosomal membranes and delays the release of enzymes from them, reduces the secretion of cytokines, inhibits the activity of neutrophils. Ketoprofena lysine salt has anti-inflammatory, analgesic and antipyretic effects. The rapid onset of action is due to the higher solubility of the lysine salt of ketoprofen compared to unchanged ketoprofen, faster and complete absorption of the active substance, which leads to the achievement of a peak of its concentration in blood plasma when taken orally in 15 minutes. The effect of the drug appears after 15–20 minutes and lasts for several hours, whereas unchanged ketoprofen reaches a maximum only 60 minutes after administration. The drug is convenient to use, because it has various forms of release: granules for the preparation of oral solution, as well as solution for rinsing (for symptomatic treatment of inflammatory oropharyngeal diseases).
Benefits:
- Innovative form of ketoprofen
- Improved lysine salt molecule
- Special microgranulation technology
- 4 times more effective in reducing headache pain compared to ibuprofen
- Unsurpassed penetration of the lymphopharyngeal ring tissue
- Easy dose selection
Limited access
This section of the site contains specialized professional information. In accordance with Federal Law of the Russian Federation No. 38-FZ “On Advertising” dated March 13, 2006, the information in this section is intended exclusively for medical and pharmaceutical workers.
Are you a medical/pharmaceutical professional?
WHERE TO BUY
Dompé Farmaceutici SpA is an Italian biopharmaceutical multinational corporation, founded in 1940 in Milan. The company pays main attention to primary medical and biotechnological activities, studies of therapeutic solutions for the treatment of rare diseases. Pharmaceutical and biotechnology projects are developed at the site of L’aquila. The headquarters are in Milan, but Dompé is also present in Naples, Boston, San Francisco, Paris, Barcelona, Berlin and Tirana.